Increased serum interleukin-34 levels as a novel diagnostic and prognostic biomarker in patients with acute ischemic stroke

Xiaoyu Huang,Fengzhan Li,Tingting Yang,Hao Li,Tan Liu,Yingying Wang,Minmin Xu,Lisha Yan,Yong Zhang,Yuzhong Wang,Linlin Fu,Deqin Geng
DOI: https://doi.org/10.1016/j.jneuroim.2021.577652
IF: 3.221
2021-09-01
Journal of Neuroimmunology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Recent data reveal that interleukin-34 (IL-34) can drive inflammatory response, thereby participating in the pathogenesis of inflammatory diseases. However, the potential effect of IL-34 in acute ischemic stroke (AIS) remains unknown. The purpose of this study was to explore whether the levels of serum IL-34 were correlated with clinical severity or prognosis in AIS patients.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>In this prospective cohort study, serum IL-34 levels were detected in 150 healthy controls and 155 AIS patients. Univariate and multivariate logistic regression analysis were conducted to investigate the effect of IL-34 on the diagnosis and prognosis of AIS. ROC curve was utilized to evaluate predictive values for IL-34.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Serum IL-34 levels at admission were significantly higher in AIS patients than those in the healthy controls. Univariate and multivariate logistics regression analysis showed that IL-34 was an independent predictor of occurrence and functional outcome of AIS. The ROC curve demonstrated that IL-34 had a good predictive effect on the diagnosis and prognosis of AIS.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>IL-34 can be used as a novel and independent diagnostic and predicting prognostic biomarker in AIS.</p>
immunology,neurosciences
What problem does this paper attempt to address?